Background-The left ventricular ejection fraction (LVEF) has prognostic and therapeutic utility after acute myocardial infarction (AMI). Although LVEF assessment is a key performance measure among AMI patients, contemporary rates of in-hospital assessment and its association with therapy use have not been well characterized. Methods and Results-We examined rates of in-hospital LVEF assessment among 77 982 non-ST-elevation myocardial infarction patients and 50 863 ST-elevation myocardial infarction patients in Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines between January 2007 and September 2009, after excluding patients who died in-hospital or who were transferred to another acute care facility, discharged to end-of-life care, or had missing LVEF assessment status. LVEF assessment increased significantly over time, with higher rates among STelevation myocardial infarction than non-ST-elevation myocardial infarction patients (95.1% versus 91.6%; P<0.001).
T he measurement of left ventricular ejection fraction (LVEF) after acute myocardial infarction (AMI) has both prognostic and therapeutic implications and is a class I clinical practice guideline recommendation, as well as a core AMI performance measure recommended by the American College of Cardiology (ACC) and American Heart Association (AHA). 1, 2 Reduced LVEF is associated with greater mortality among patients with coronary artery disease 3 and predicts increased risks of early all-cause mortality, 4 as well as sudden cardiac death 5 after AMI. Improvement of LVEF with revascularization is associated with improved long-term survival among AMI patients. 6 Clinical practice guidelines provide several therapeutic recommendations for both the acute and long-term postdischarge management of AMI based on LVEF. Specifically, indications for angiotensinconverting-enzyme inhibitor (ACE-I), angiotensin receptor blockers (ARB), and aldosterone antagonists are LVEF dependent. 2, 7 Given that assessment of primary prevention implantable cardioverter-defibrillator candidacy after AMI is also determined primarily by LVEF, 8 patients with reduced LVEF during the AMI hospitalization require appropriate follow-up care to avoid missed prevention opportunities.
The National Cardiovascular Data Registry (NCDR) Acute Coronary Treatment and Intervention Outcomes Network Registry-Get with the Guidelines (ACTION Registry-GWTG) affords the opportunity to (1) examine the frequency of LVEF assessment among contemporary patients with non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial infarction (STEMI), (2) better understand patient and hospital-level factors associated with failure to assess LVEF at the time of AMI, and (3) assess the relationship between LVEF assessment and medications and interventions prescribed at discharge. 
Methods

Data Source
ACTION
Patient Population
This analysis primarily examined patients from ACTION Registry-GWTG with NSTEMI or STEMI from 2007 to 2009. Data from 147 165 patients treated at 383 participating centers were included in the analysis. We excluded patients who were transferred to another institution during the index hospitalization (n=9768) or who died inhospital (n=6637) as they may not have had the opportunity for ejection fraction assessment at the ACTION hospital ( Figure 1) . We also excluded patients who were discharged to end-of-life or hospice care, whose goals of care would minimize diagnostic testing and therapeutic intervention (n=1555), those discharged against medical advice (n=259), and those missing LVEF assessment status (n=101). Our final study population included 77 982 STEMI and 50 863 NSTEMI patients treated at 379 US centers. To provide a historical perspective, we also examined LVEF assessment rates of NSTEMI patients captured in the CRUSADE Registry from 2002 to 2006, using similar inclusion and exclusion criteria.
Data Definition
LVEF assessment is based on medical record documentation between the time of patient arrival at first care facility and discharge. Data for patients transferred to an ACTION hospital for AMI care were retrospectively abstracted based on medical records sent with the patient; thus, initial presenting features and LVEF assessment at the referral hospital may be captured. When multiple ejection fractions are obtained during the index admission, the Registry specifies that the measurement obtained closest to discharge be used. In accordance with clinical practice guidelines and performance measures, LVEF can be assessed via invasive (eg, left ventriculogram) or noninvasive (eg, echocardiogram, scintigraphy) imaging and can be characterized quantitatively or qualitatively with normal or good function defined as LVEF ≥50%. 1, 9 Weekday presentation in the Registry is defined as presentations occurring from Monday at 8 AM to Friday at 5 PM.
Defect-free care is a hospital-level composite performance measure used in ACTION Registry-GWTG, which is defined as patients receiving acute and discharge guideline measures endorsed by the 2008 ACC/AHA Performance Measures statement in the absence of contraindications: reperfusion (for STEMI patients only, with time to lytic of ≤30 minutes and time to percutaneous coronary intervention of ≤90 minutes), evaluation of LVEF, smoking-cessation counseling, aspirin on arrival, and discharge on aspirin, β-blocker, ACE-I or ARB, if indicated, statin, and referral to cardiac rehabilitation. 1 In this analysis, we used a modified version of defect-free care, removing LVEF assessment, our independent variable, from this composite variable.
Indication for aldosterone use was defined as any one of heart failure on admission, in-hospital heart failure, or LVEF <40% among patients with diabetes mellitus, or LVEF <40% and either heart 
WHAT IS KNOWN
• In patients with acute myocardial infarction, the appropriate medical regimen and subsequent management are dependent, in part, on residual left ventricular function. Therefore, assessment of left ventricular ejection fraction is a class I guideline recommendation for patients after an acute myocardial infarction.
WHAT THE STUDY ADDS
• This analysis demonstrates overall high rates of left ventricular ejection fraction assessment in recent years; however, significant variability in assessment rate exists between hospitals.
• Importantly, hospitals with lower rates of left ventricular ejection fraction assessment are associated with lower quality of care for patients with acute myocardial infarction.
• Patient in whom left ventricular function is not assessed were less likely to receive evidence-based therapy and care.
failure on admission or in-hospital heart failure for patients without diabetes mellitus, excluding patients with elevated initial serum creatinine levels (>2.5 mg/dL in men or >2.0 mg/dL in women) or contraindications to aldosterone antagonists. Note that aldosterone use, which was indicated in a small minority of patients, is not included in the defect-free care variable.
Statistical Analysis
Patient demographics and clinical history, presenting clinical features, in-hospital procedures and outcomes, and hospital characteristics were compared between cases in which LVEF was and those in which it was not assessed, stratified by type of AMI (NSTEMI and STEMI). Continuous variables were presented as medians with 25th and 75th percentiles along with mean (SD), and categorical variables were expressed as frequencies with percentages. Continuous and ordinal categorical variables were compared using Wilcoxon rank-sum tests, whereas nominal categorical variables were compared using χ 2 tests. Because patients with prior heart failure may have had recent LVEF assessment before the myocardial infarction (MI) hospitalization, we conducted a secondary analysis examining the incidence of LVEF assessment among patients without prior heart failure.
To determine the independent factors associated with non-LVEF assessment, the logistic generalized estimating equations method with exchangeable working correlation matrix was used to account for within-hospital clustering because patients at the same hospital are more likely to have similar responses relative to patients at other hospitals (ie, within-center correlation for responses). 10 This method produces estimates similar to those from ordinary logistic regression, but variances are adjusted for the correlation of outcomes within a hospital. Variables were selected for multivariable analysis based on a priori clinical judgment. Continuous variables were tested for linearity and plotted against rates of outcome to create dichotomous cut-off points, where applicable. These cut-off points were considered where the relationship between the variable and non-LVEF assessment was flat or nonlinear. For example, there was a J-shaped relationship between weight and unadjusted LVEF nonassessment; therefore, we analyzed it as a dichotomous variable by allowing for 2 slopes via fitting a linear spline with a knot at 100 kg. We conducted several hospital-level analyses to explore patterns of LVEF assessment across hospitals and to correlate it with composite quality of AMI care (defect-free care rates). In these analyses, we excluded hospitals with <20 AMI admissions (45 hospitals treating 363 patients) to ensure a stable threshold of assessment. Spearman correlation coefficients were calculated between hospital LVEF assessment rates and hospital defect-free care rates for the overall sample and by NSTEMI and STEMI. Although patients facing end-of-life care were excluded from the study population, a concern remained that hospitals treating older patients would have lower rates of LVEF assessment. We, therefore, used nonlinear mixed models, 11 fitting hospital as a random effect and adjusting for patient age, to assess age-adjusted hospital LVEF measurement and defect-free care rates. From the models, the predicted probability for each patient was obtained, then averaged for each hospital to calculate hospital age-adjusted rates. Patient demographics and clinical history, presenting clinical features, and hospital characteristics were compared across quartiles of age-adjusted hospital LVEF assessment rates. Unadjusted and age-adjusted hospital defect-free care rates were compared between patients with and without LVEF assessment.
Finally, we compared use of guideline-recommended therapies at discharge, specifically aspirin, β-blocker, ACE-I or ARB, aldosterone antagonist, and statin use, as well as cardiac rehabilitation referral, between patients with and without LVEF assessment. Multivariable logistic generalized estimating equations modeling was used to adjust for potential confounders, including patient demographics (age, weight, sex, race, and insurance type), laboratory values (baseline creatinine, hemoglobin, and troponin), medical history (prior heart failure, MI, coronary artery bypass graft, percutaneous intervention, diabetes mellitus, hypertension, peripheral arterial disease, or stroke), clinical presentation (initial blood pressure, initial heart rate, heart failure on admission, and NSTEMI versus STEMI), hospital characteristics (hospital defect-free care, presence of surgical capabilities, academic versus nonacademic, and number of beds), and time of presentation (weekday versus weekend).
P<0.05 was considered statistically significant for all tests, and all tests of statistical significance were 2-tailed. All analyses were performed by the NCDR ACTION Registry-GWTG data analysis center at the Duke Clinical Research Institute using SAS software (version 9.2, SAS Institute, Cary, NC). Baseline clinical characteristics were compared between patients with and without LVEF assessment for both NSTEMI and STEMI (Table 1) . For both NSTEMI and STEMI, patients in whom LVEF was not assessed were older. NSTEMI patients without LVEF assessment were more likely to be women, but no sex difference was observed in STEMI LVEF assessment. In general, clinical comorbidities were more frequent among patients without LVEF assessment, including prior MI, prior heart failure, prior revascularization, and cardiovascular risk factors. NSTEMI patients who received LVEF assessment were less likely to have signs of heart failure or cardiogenic shock on admission; however, when patients with a history of heart failure were excluded from analysis, this pattern was no longer observed (onlineonly Data Supplement Table I ).
Results
Patterns of LVEF Assessment Among STEMI and NSTEMI Patients
Hospital-Level Variation in LVEF Assessment
LVEF assessment rate varied across geographic regions for both NSTEMI and STEMI (Table 2 ). For patients with NSTEMI, there was a small difference in the rate of patients treated at teaching hospitals among patients with LVEF assessment versus those without (27.1% versus 28.5%; P=0.019). A larger difference (29.4% versus 24.0%; P<0.0001) was present for STEMI patients. For both NSTEMI and STEMI, the facility's number of beds was significantly higher for cases in which LVEF was assessed. LVEF assessment did not seem to vary with weekend versus weekday hospital admission for NSTEMI patients, but a small difference was observed for STEMI patients. Although there was a statistically significant difference in length of stay between patients with and without LVEF assessment, the absolute difference was small, suggesting the difference was not clinically meaningful. We performed several hospital-level analyses to examine variation in LVEF assessment rates across hospitals and to correlate this with hospital-level quality of AMI care. The unadjusted rate of hospital defect-free care was higher among patients for whom LVEF was assessed than for those without 
0001).
Because increasing age is likely to be associated with less aggressive care, we examined age-adjusted hospital LVEF assessment rates and found these to range widely across hospitals from 26% to 100%, with a median of 93.6% and interquartile range from 88.4% to 96.2% (Figure 3) . Age-adjusted defect-free care rates remained higher for patients with LVEF assessment (median 90.2% [25th, 75th percentiles of 64.1%, 99.9%]) than for those without LVEF assessment (median 80.0% [25th, 75th percentiles of 50.2%, 90.6%]; P<0.0001). When hospital were stratified by quartiles of age-adjusted LVEF assessment rates, statistically significant differences were noted for many of the patient characteristics between quartiles, yet clinical differences were mostly small (Table 3) . Lower LVEF assessment hospitals were smaller, and less commonly had academic affiliations, surgery capability, or PCI capability compared with hospitals that assessed LVEF more frequently.
Factors Associated With LVEF Nonassessment
In multivariable modeling combining patient and hospital characteristics, increasing age had the strongest association with LVEF nonassessment (Figure 4) . Prior coronary revascularization, prior infarct, and prior heart failure were all associated with lower likelihood of LVEF assessment. NSTEMI patients remained less likely than STEMI patients to receive LVEF assessment. Patients with heart failure or cardiogenic shock on admission were more likely to be associated with LVEF assessment than those without heart failure or cardiogenic shock. Among hospital features, a lower composite AMI defect-free care score was associated with lower likelihood of LVEF assessment, whereas the association between academic status and LVEF assessment was not significant. 4.4% versus 3.3%; P=0.0002) during the index hospitalization than patients whose LVEF was not assessed. Among patients without documented contraindications, discharge prescription rates for evidence-based secondary prevention medications, such as aspirin, β-blockers, ACE-I or ARB, and statins were all lower in NSTEMI and STEMI patients without LVEF assessment compared with those for whom LVEF was assessed (Table 4) . Cardiac rehabilitation referral rates were also higher among eligible patients with LVEF assessment. The use of ACE-I or ARB and aldosterone antagonists, indicated for patients with abnormal LVEF, occurred more frequently among patients with more severe LVEF reduction. Among patients with a creatinine level ≤2.5 mg/dL and without documented contraindications, aldosterone antagonists were prescribed in 13.7% of STEMI patients and 11.6% of NSTEMI patients meeting an indication for their use (which included an LVEF restriction, such that these patients by definition had LVEF assessed during their index hospitalization). After multivariable adjustment, in-hospital LVEF assessment was significantly associated with increased discharge prescription of all medication classes, as well as cardiac rehabilitation (Table 4 ).
In-Hospital Outcomes and Evidence-Based
Discussion
Our study shows high rates of LVEF assessment among contemporary treated AMI patients, with a significant increase during the past decade. However, significant variability in LVEF assessment rates across hospitals remains. Although patient age and clinical comorbidities contribute to individual decision making for LVEF assessment, hospitals with lower composite AMI care quality are less likely to perform LVEF assessments. Importantly, patients in whom LVEF was not assessed were significantly less likely to be discharged on evidence-based medications in the absence of contraindications and were less likely to receive smoking-cessation counseling and referral to cardiac rehabilitation, suggesting systematic undertreatment of this subset of patients. These results suggest that quality improvement efforts are indicated, particularly for the hospitals in the lowest quartile of LVEF assessment, where such efforts are expected to yield the greatest interval improvement. Clinical practice guidelines have incorporated the assessment of LVEF as a core performance measure for patients with STEMI and NSTEMI, 1 because LVEF has both prognostic and therapeutic significance for these patients. Left ventricular systolic dysfunction after AMI predicts long term-mortality, 4 and a reduced LVEF may prompt greater consideration of invasive treatment. Furthermore, the optimization of post-MI medical therapies are predicated, in part, on left ventricular systolic function; 1 thus, knowledge of LVEF during the index MI hospitalization is needed to guide care strategy. In contrast to the LVEF assessment performance measure for heart failure patients, 12 because the AMI may acutely affect LVEF results, LVEF assessments performed before the AMI hospitalization have been deemed to not meet the AMI performance measure. 1 Previous studies have shown wide variations in LVEF assessment patterns across practices. Retrospective data from Olmstead County from 1979 to 1986 demonstrated a rapid increase in LVEF assessment from 22% to 85% among AMI patients, with ≈80% of assessments occurring before hospital discharge. 13 Rates of LVEF assessment in another regional study (Worcester, MA) were consistently lower, with an initial assessment rate of 4% in 1975 and 58% in 1984, after which they slowly rose to ≈70% as of 1991. 14, 15 Our study of the National Cardiovascular Data Registry permits characterization of contemporary treatment patterns beyond single-center or regional experiences and shows progressively increasing rates of LVEF assessment in the United States during the past decade, likely in response to guideline recommendations reinforced by the ACC/AHA AMI performance measures, 1 as well as the need to define LVEF to guide appropriate medical therapy. 2, 7 The rates of LVEF assessment observed in this study are much higher than those reported in Canada between 1999 and 2008. As in the present study, Canadian LVEF assessment rates in NSTEMI patients increased significantly over time, but only 69% of patients underwent LVEF assessment during the index admission in 2008 16 compared with 91.7% in that same year in the present analysis.
Similar to previous studies, 13 we showed that older age and greater comorbidities, particularly history of myocardial infarction, revascularization, or heart failure, were associated with lower rates of LVEF ascertainment. Of note, length of stay has previously been demonstrated to influence rate of LVEF assessment. 16, 17 As such, the ACC/AHA LVEF assessment performance measure gives credit for AMI patients with a documented plan for LVEF testing after discharge, given potentially limited opportunities to test during abbreviated hospital stays or weekend admissions. Although our study did not capture intent for postdischarge LVEF assessment, we found no significant difference in weekday versus weekend presentation or length of stay between patients with and without LVEF assessment. We did, however, observe a correlation between the rates of hospital defect-free care and LVEF assessment, suggesting that LVEF assessment may be a marker of AMI quality of care. Prior work has shown that for both heart failure and AMI admissions, LVEF documentation rates are on the order of 93% for hospitals receiving awards for GWTG adherence compared with 83% for other hospitals, 18 supporting the hypothesis that LVEF assessment rates reflect overall quality.
Finally, failure to assess LVEF was associated with deficits in evidence-based therapy prescription. This parallels the findings of a Canadian NSTEMI study that showed failure to assess LVEF to be associated with lower evidence-based medication use. 16 Guidelines recommend ACE-I/ARB therapy among post-MI patients with reduced ejection fraction. 1, 2 Yet, interestingly, our study found that only 85% of patients with LVEF <40% were prescribed ACE-I/ARB in the absence of contraindications. This is in contrast to national performance summary data from the Joint Commission that observed prescription rates of 92% in 2007 and 94% in 2008. 19 Although there is a growing body of evidence supporting the use of aldosterone antagonists in specific populations, [20] [21] [22] aldosterone antagonist prescription rates were even lower (12%) in this study among eligible patients meeting indications for their use.
Although ACE-I/ARB and aldosterone antagonist use postinfarct is focused on patients with reduced LVEF, other therapies such as β-blockers, statins, and cardiac rehabilitation referral have observed benefits independent of the level of systolic function. 2, 7 The fact that patients with in-hospital LVEF assessment were more likely to receive these therapies again supports the notion that LVEF assessment may be a marker of in-hospital quality of care. In contrast to a prior study that found patients with LVEF <40% were more likely to be discharged on a β-blocker (26% increase in likelihood) after AMI compared with those with LVEF >40%, 23 our analysis did not find significant differences in β-blocker use between patients with and without demonstrated systolic dysfunction. However, similar to a previous study, a significantly lower rate of cardiac rehabilitation referral was observed for NSTEMI patients with LVEF<40%. 24 
Limitations
Our results need to be considered in light of several data limitations. First, the action Registry-GWTG database only captures in-hospital events; as such, patients who are discharged with a plan for outpatient LVEF assessment are deemed LVEF not assessed. Although current performance measures allow for postdischarge planned LVEF assessment, 1 discharge medical therapy optimization depends, in part, on post-AMI left ventricular function. We, therefore, argue that assessment of actual LVEF assessment is of more value than planned outpatient LVEF assessment. It is important to note that in the analysis population of 128 845, only 101 subjects were excluded for missing LVEF assessment status, underscoring the thoroughness with which NCDR documentation is compiled and submitted. Although the mode of LVEF assessment was not standardized across the cohort, the Registry reflects real-world practice patterns and the clinical information that is available to practitioners. Second, repeat LVEF assessment among patients with prior severe left ventricular systolic dysfunction may not provide incremental prognostic value, because these patients may already meet criteria for ACE-I/ ARB and implantable cardioverter defibrillator consideration. As the ACTION Registry-GWTG registry does not capture LVEF values before hospital presentation, we cannot exclude these patients; however, we observed similar rates of inhospital LVEF assessment even after excluding patients with prior heart failure, for whom prior LVEF assessments may have been previously performed. Finally, although the Registry represents a wide spectrum of hospital types and sizes, participation is voluntary and may reflect an inherent hospital interest in quality improvement. Thus, these results may not be generalizable to all hospitals in the United States.
Conclusions
LVEF assessment rates have risen over time in ACTION Registry-GWTG enrolling centers, currently exceeding 92% for patients with NSTEMI and 95% in patients presenting with STEMI, yet significant interhospital variability remains. Failure to assess LVEF was associated with lower hospital composite quality of care, as well as lower rates of guideline-recommended therapy use at discharge. These patients represent targets for future quality improvement efforts, particularly at hospitals in the lowest quartile of performance on this metric.
